Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00042068
Recruitment Status : Completed
First Posted : July 24, 2002
Last Update Posted : November 1, 2013
Information provided by:
Boehringer Ingelheim

Brief Summary:
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: Meloxicam Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis
Study Start Date : June 2002
Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Meloxicam

Primary Outcome Measures :
  1. Response according to American College of Rheumatology 20% (ACR20) classification [ Time Frame: at 12 weeks ]

Secondary Outcome Measures :
  1. Number of painful or tender joints [ Time Frame: up to 12 weeks ]
  2. Number of swollen joints [ Time Frame: up to 12 weeks ]
  3. Patient's global (overall) assessment of disease activity [ Time Frame: up to 12 weeks ]
  4. Investigator's global (overall) assessment of disease activity [ Time Frame: up to 12 weeks ]
  5. Patient's assessment of pain [ Time Frame: up to 12 weeks ]
  6. Patient's assessment of physical function (mHAQ) [ Time Frame: up to 12 weeks ]
  7. C-Reactive Protein (CRP) [ Time Frame: up to 12 weeks ]
  8. Withdrawal due to lack of efficacy [ Time Frame: up to 12 weeks ]
  9. Duration of morning stiffness [ Time Frame: up to of 12 weeks ]
  10. Patient's final global (overall) assessment of efficacy [ Time Frame: at end of 12 weeks ]
  11. Investigator's final global (overall) assessment of efficacy [ Time Frame: at end of 12 weeks ]
  12. Patient status with regard to change in arthritic condition [ Time Frame: at end of 12 weeks ]
  13. Use of rescue medication [ Time Frame: up to 12 weeks ]
  14. Incidence and intensity of adverse events [ Time Frame: until 4 weeks post treatment ]
  15. Patient's final global assessment of tolerability [ Time Frame: at end of 12 weeks ]
  16. Investigator's final global assessment of tolerability [ Time Frame: at end of 12 weeks ]
  17. Withdrawals due to adverse events [ Time Frame: at end of 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than or equal to 18 and less than or equal to 80
  • Diagnosis of Rheumatoid Arthritis for at least six weeks
  • Taking an NSAID
  • If female: using adequate contraception
  • Willingness to stop current NSAID until criteria reached to begin study drug
  • Able to provide written informed consent

Exclusion Criteria:

  • Intolerance or hypersensitivity to NSAIDs or ingredients of trial drug
  • Pregnancy, lactating
  • Use of investigational drug within 30 days prior to entering the trial
  • History of peptic ulcer or of gastrointestinal hemorrhage except simple hemorrhoidal bleeding
  • History of cerebrovascular or other bleeding disorder
  • Severe hypertension
  • Other disease that might interfere with safety of the patient or evaluation of trial drug (investigator's opinion)
  • RA of functional class IV
  • Synovectomy in any large joint within the past 6 months prior to entering the trial or planned during trial
  • Concomitant therapy with anticoagulant, therapeutic doses of aspirin, phenothiazines, lithium, chronic GI-medication, analgesic drug (except acetaminophen up to 4 grams/day)
  • DMARDs initiated within past three months or dose changed less than two months before entering the trial
  • Therapy with corticosteroids exceeding 10 mg/day prednisone equivalent or change in dose within 1 month before trial
  • Concomitant therapy with ACTH within past month before entering the trial.
  • History of narcotic or alcohol abuse (past 12 months)
  • Abnormal laboratory values
  • Previous participation in the present trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00042068

Show Show 153 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Study Coordinator Boehringer Ingelheim Ltd./Bracknell
Additional Information:
Layout table for additonal information Identifier: NCT00042068    
Other Study ID Numbers: 107.258
First Posted: July 24, 2002    Key Record Dates
Last Update Posted: November 1, 2013
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action